Digest Network Come funziona
Network
/
Società
Ag
Non verificato

Agenus Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

80 comunicati stampa

Guarda tutti i comunicati
10/09/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
31/08/2026
Eventi
Web e Social Network
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus to Participate in Upcoming September Investor Conferences
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
28/08/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
26/08/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
06/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Oncologia
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
28/07/2026
Web e Social Network
Finanza
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
17/07/2026
Eventi
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
13/07/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Web e Social Network
Telefonia e Varie
Mercato azionario
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
06/07/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
25/06/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0